dc.contributor
Institut Català de la Salut
dc.contributor
[Folprecht G] University Hospital Carl Gustav Carus, University Cancer Center, Dresden, Germany. [Morfouace M] Institut Gustave Roussy, Villejuif, France. EORTC, Brussels, Belgium. [Collienne M] EORTC, Brussels, Belgium. Universitätsmedizin Mannheim, Mannheim, Germany. [Salazar R] Catalan Institute of Oncology, Barcelona, Spain. [Stein A] University Medical Center Hamburg-Eppendorf, Hamburg, Germany. [Elez E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Folprecht, Gunnar
dc.contributor.author
Morfouace, Marie
dc.contributor.author
Collienne, Maike
dc.contributor.author
Salazar, Ramon
dc.contributor.author
Stein, Alexander
dc.contributor.author
Elez, Elena
dc.date.accessioned
2025-10-25T05:39:14Z
dc.date.available
2025-10-25T05:39:14Z
dc.date.issued
2025-06-04T12:36:02Z
dc.date.issued
2025-06-04T12:36:02Z
dc.identifier
Folprecht G, Morfouace M, Collienne M, Salazar R, Stein A, Elez E, et al. European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor.’ ESMO Gastrointest Oncol. 2025 Jun;8:100168.
dc.identifier
http://hdl.handle.net/11351/13201
dc.identifier
10.1016/j.esmogo.2025.100168
dc.identifier.uri
http://hdl.handle.net/11351/13201
dc.description.abstract
Screening platform; Colorectal cancers; Targeted treatment
dc.description.abstract
Plataforma de cribratge; Càncers colorectals; Tractament dirigit
dc.description.abstract
Plataforma de cribado; Cánceres colorrectales; Tratamiento dirigido
dc.description.abstract
Background
The European Organisation for Research and Treatment of Cancer (EORTC) has established the Screening Platform for Efficient Clinical Trial Access for COLORectal Patients (SPECTAcolor), which provides centralized molecular testing to screen patients for and facilitate enrollment in molecular-based therapeutic trials.
Materials and methods
Patients with advanced or metastatic colorectal malignancies were recruited in 11 European countries. Patients’ paraffin-embedded material was tested for KRAS, NRAS, BRAF, and PI3K microsatellite instability-high (MSI-H) (not routine at the time of recruitment) and later by a 300-gene next-generation sequencing panel. RNA profiling was carried out in a subset of patients. Results were reported to the centers and patients were followed up for their clinical outcome.
Results
Recruitment began in September 2013. The molecular screening program was completed at the end of 2015. A total of >1000 patients were prospectively recruited into SPECTAcolor. Molecular and complete clinical/follow-up data are available for 845 metastatic colorectal cancer (CRC) patients. The simple κ coefficient for the agreement between local and central testing for KRAS, NRAS, and BRAF was 0.82-0.95, and the κ for MSI-H was 0.55. The median overall survival was 56.6 months. Patients with BRCA, FGFR, and HER2 alterations had a trend toward shorter survival.
Conclusion
SPECTAcolor demonstrated that recruitment to an academic screening platform is feasible and that central (quality-assured) testing may remain necessary even for commonly tested markers. SPECTAcolor has generated a clinical and molecular dataset with associated samples for >800 CRC patients for future academic research such as biomarker validation. Linking screening platforms to therapeutic trials and ensuring sustainability remain challenging.
dc.description.abstract
SPECTAcolor was supported by a grant of Walgreens Boots Alliance to the EORTC (no grant number).
dc.format
application/pdf
dc.relation
ESMO Gastrointestinal Oncology;8
dc.relation
https://doi.org/10.1016/j.esmogo.2025.100168
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Còlon - Càncer - Tractament
dc.subject
Recte - Càncer - Tractament
dc.subject
Cribatge (Medicina)
dc.subject
Diagnòstic molecular
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Mass Screening
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Molecular Diagnostic Techniques
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::cribado sistemático
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas de diagnóstico molecular
dc.title
European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
